Pancreatic Cancer Research

ResearcherDüsseldorf University HospitalActive in the last 2 years

Wolfram Trudo Knoefel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2472-8314; OpenAlex author ID A5083695901, A5108563202, A5109740424, A5129131105. Sources: OpenAlex.

Their work

Papers
23 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
74
Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: 3 papers · 2023: 3 papers · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 23

  1. Standardizing computed tomographic assessment of the mesopancreas in pancreatic cancer patients. Co-author DOI 10.1007/s00261-026-05486-1↗
  2. Correction: Standardizing computed tomographic assessment of the mesopancreas in pancreatic cancer patients. Co-author DOI 10.1007/s00261-026-05656-1↗
  3. The Mesopancreas remains at risk in primary resectable pancreatic cancer patients: time to reappraise resectability criteria? Co-author DOI 10.1016/j.ctarc.2026.101176↗
  4. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7↗
  5. Stroma and lymphocytes identified by deep learning are independent predictors for survival in pancreatic cancer. Co-author DOI 10.1038/s41598-025-94362-x↗
  6. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… Co-author DOI 10.1016/j.ejca.2022.12.009↗
  7. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype. Co-author DOI 10.1136/gutjnl-2021-326550↗
  8. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis. Co-author DOI 10.1186/s12943-023-01880-1↗
  9. N, LNR or LODDS: Which Is the Most Appropriate Lymph Node Classification Scheme for Patients with Radically Resected Pancreatic Cancer? Co-author DOI 10.3390/cancers14071834↗
  10. Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14143494↗
  11. Quality of Life in Patients with Pancreatic Cancer before and during the COVID-19 Pandemic. Last author DOI 10.3390/ijerph19063731↗
  12. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Last author DOI 10.1016/j.pan.2021.02.024↗
  13. Pancreatic ductal adenocarcinoma concomitant with pancreatic metastases of clear-cell renal cell carcinoma: a case report. Co-author DOI 10.1186/s13256-021-02768-8↗
  14. Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Last author DOI 10.3390/cancers14010068↗
  15. Peridural Anesthesia and Cancer-Related Survival after Surgery for Pancreatic Cancer-A Retrospective Cohort Study. Co-author DOI 10.3390/clinpract11030070↗
  16. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer. Co-author DOI 10.15252/embj.2019102808↗
  17. Stromal heterogeneity in pancreatic cancer and chronic pancreatitis. Co-author DOI 10.1016/j.pan.2018.05.004↗
  18. Isolation of circulating tumor cells from pancreatic cancer by automated filtration. Co-author DOI 10.18632/oncotarget.21026↗
  19. [Resection for advanced pancreatic cancer following multimodal therapy]. Last author DOI 10.1007/s00104-016-0184-3↗
  20. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis. Last author DOI 10.1371/journal.pone.0130192↗
  21. Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin. Last author DOI 10.1007/s12029-012-9380-7↗
  22. Losses at chromosome 4q are associated with poor survival in operable ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2011.11.001↗
  23. Vascular invasion in pancreatic cancer: tumor biology or tumor topography? Last author DOI 10.1016/j.surg.2012.05.012↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Iréne Esposito · 14 shared papers, 2017–2026 · strength 2.19
  2. Sami Alexander Safi · 10 shared papers, 2018–2026 · strength 1.68
  3. A. Alexander · 7 shared papers, 2012–2026 · strength 1.16
  4. Lena Häberle · 8 shared papers, 2018–2023 · strength 1.00
  5. Farid Ziayee · 4 shared papers, 2021–2026 · strength 0.94
  6. Lena Haeberle · 3 shared papers, 2026 · strength 0.81
  7. Stephan O. David · 3 shared papers, 2026 · strength 0.81
  8. Tom Luedde · 5 shared papers, 2021–2025 · strength 0.75
  9. Alexander Rehders · 7 shared papers, 2012–2022 · strength 0.75
  10. Andreas H. Krieg · 4 shared papers, 2015–2022 · strength 0.49
  11. Nikolas Hendrik Stoecklein · 4 shared papers, 2012–2023 · strength 0.38
  12. Thilo Hackert · 2 shared papers, 2023–2025 · strength 0.29
  13. Christian Vay · 2 shared papers, 2022 · strength 0.29
  14. Anna Melissa Schlitter · 2 shared papers, 2018–2023 · strength 0.24
  15. Xiuxiang Tan · 1 shared paper, 2025 · strength 0.19
  16. Lara Rosaline Heij · 1 shared paper, 2025 · strength 0.19
  17. Edgar Dahl · 1 shared paper, 2025 · strength 0.19
  18. Evelien J.M. de Jong · 1 shared paper, 2025 · strength 0.19
  19. Michail Doukas · 1 shared paper, 2025 · strength 0.19
  20. Bas Groot Koerkamp · 1 shared paper, 2025 · strength 0.19
  21. Georg J. Wiltberger · 1 shared paper, 2025 · strength 0.19
  22. Judith de Vos‐Geelen · 1 shared paper, 2025 · strength 0.19
  23. Casper H.J. van Eijck · 1 shared paper, 2025 · strength 0.19
  24. Shivan Sivakumar · 1 shared paper, 2025 · strength 0.19
  25. Marina Lesina · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.